Pandora Media (P) just came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.21 per share a year ago. These figures are adjusted for non-recurring items. […]
Fiserv (FISV) just came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.74 per share. This compares to earnings of $0.60 per share a year ago. […]
Whiting Petroleum (WLL) just came out with quarterly earnings of $0.62 per share, in line with the Zacks Consensus Estimate. This compares to loss of $0.72 per share a year ago. These figures are adjusted for non-recurring items […]
Extra Space Storage (EXR) just came out with quarterly earnings of $1.15 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.09 per share a year ago. These figures are adjusted for non-recurring items […]
Newfield Exploration (NFX) just came out with quarterly earnings of $0.94 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.43 per share a year ago. These figures are adjusted for non-recurring items […]
Douglas Emmett (DEI) just came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.47 per share a year ago. […]
Blue Capital Reinsurance (BCRH) just came out with quarterly earnings of $0.28 per share, missing the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.52 per share a year ago. […]
Eversource Energy (ES) just came out with quarterly earnings of $0.76 per share, beating the Zacks Consensus Estimate of $0.75 per share. This compares to earnings of $0.72 per share a year ago. These figures are adjusted for non-recurring items […]
Rogers Corp. (ROG) just came out with quarterly earnings of $1.19 per share, missing the Zacks Consensus Estimate of $1.33 per share. This compares to earnings of $1.33 per share a year ago. […]
Anadarko Petroleum (APC) just came out with quarterly earnings of $0.54 per share, missing the Zacks Consensus Estimate of $0.60 per share. This compares to loss of $0.77 per share a year ago. […]
ArcBest (ARCB) just came out with quarterly earnings of $1.12 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.57 per share a year ago. […]
Qiagen (QGEN) just came out with quarterly earnings of $0.33 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.30 per share a year ago. These figures are adjusted for non-recurring items. […]
NuVasive (NUVA) just came out with quarterly earnings of $0.58 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.46 per share a year ago. […]
Evertec (EVTC) just came out with quarterly earnings of $0.46 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.44 per share a year ago. […]
Terex (TEX) just came out with quarterly earnings of $0.98 per share, beating the Zacks Consensus Estimate of $0.90 per share. This compares to earnings of $0.51 per share a year ago. These figures are adjusted for non-recurring items. […]
Big 5 Sporting Goods (BGFV) just came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.11. This compares to earnings of $0.13 per share a year ago. These figures are adjusted for non-recurring items. […]
Horizon Technology Finance (HRZN) just came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.24 per share a year ago. These figures are adjusted for non-recurring items. […]
W.M. Barr to Become #1 Company in Outdoor Cleaning With the Acquisition of Spray & Forget Brand PR Newswire MEMPHIS, Tenn., July 31, 2018 MEMPHIS, Tenn. […]
Laekna Acquires Exclusive Worldwide Rights to Two Clinical Stage Oncology Assets Laekna to Develop and Commercialize Two Oral Akt Inhibitors with Positive Proof-of-concept Results PR Newswire SHANGHAI, July 31, 2018 SHANGHAI , July 31, 2018 /PRNewswire/ — Laekna Inc., a biotechnology company headquartered in Shanghai , announced today the signing of an agreement with Novartis Pharma AG for exclusive global rights to develop and commercialize two oral Novartis clinical-stage oncology assets. The candidates are oral pan-Akt kinase inhibitors. Over ten clinical Phase I/II studies for afuresertib (ASB183) and uprosertib (UPB795) have been conducted in several cancer indications including ovarian and gastric cancer, multiple myeloma, melanoma, and other indications. […]
Cheesecake Factory (CAKE) just came out with quarterly earnings of $0.65 per share, missing the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.78 per share a year ago. […]
Copyright © 2024 | MH Magazine WordPress Theme by MH Themes